Watson's Generic Lidoderm(R) Receives FDA Approval

              Watson's Generic Lidoderm(R) Receives FDA Approval

PR Newswire

PARSIPPANY, N.J., Aug. 23, 2012

PARSIPPANY, N.J., Aug. 23, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.,
has received final approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm^®.
Watson plans to launch the product in September of 2013 pursuant with its
settlement agreement with Endo Pharmaceuticals Inc. and believes that under
Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity.

On May 29, 2012, Watson announced it had entered into an agreement with Endo
Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding
patent litigation related to Watson's generic version of Lidoderm®. The
agreement allows Watson to launch its lidocaine topical patch 5% product on
September 15, 2013.

For the twelve months ending June 30, 2012, Lidoderm® had total U.S. sales of
approximately $1.2 billion according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical
company. The Company is engaged in the development, manufacturing, marketing
and distribution of generic pharmaceuticals and specialized branded
pharmaceutical products focused on Urology and Women's Health. The Company is
also developing biosimilar products in Women's Health and Oncology. 
Additionally, Watson distributes generic and branded pharmaceuticals through
its Anda, Inc. distribution business.  Watson has operations in many of the
world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Watson's current perspective of
existing information as of the date of this release. It is important to note
that Watson's goals and expectations are not predictions of actual
performance. Actual results may differ materially from Watson's current
expectations depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others, the impact
of competitive products and pricing; risks that resolution of patent
infringement litigation through settlement could result in investigations or
actions by private parties or governmental agencies or authorities; the timing
and success of product launches; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and materials;
successful compliance with FDA and other governmental regulations applicable
to Watson and its third party manufacturers' facilities, products and/or
businesses; changes in the laws and regulations, including Medicare and
Medicaid, affecting among other things, pricing and reimbursement of
pharmaceutical products;  the inherent uncertainty of financial projections;
and such other risks and uncertainties detailed in Watson's periodic public
filings with the Securities and Exchange Commission, including but not limited
to Watson's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012
and Watson's Annual Report on Form 10-K for the year ended December 31, 2011.
Except as expressly required by law, Watson disclaims any intent or obligation
to update these forward-looking statements.

Lidoderm^® is a registered trademark of Hind Health Care, Inc.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Media:
          Charlie Mayr
          (862) 261-8030

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.

Website: http://www.watson.com